What Drives Country Differences in Cost of Alzheimer’s Disease? An Explanation from Resource Use in the GERAS Study

Manuscript Number: 

16-0449R2

Author(s): 
Josep M. Argimon, Mark Belger, Giuseppe Bruno, Richard Dodel, Michael Happich, Josep Maria Haro, Roy W. Jones, Catherine Reed, Bruno Vellas, Anders Wimo

Disclosures

Josep M. Argimon

  • Consulting Fees:
    I received in the past (not in the last two years) a fee for the design of GERAS study

Mark Belger

  • Equity:
    Hold shares in Eli Lilly
    Sponsors:
    Full time employee of Eli Lilly as a Principal Research Scientist

Giuseppe Bruno

  • Consulting Fees:
    Lilly, advisory board GERAS Grifols Consultant Omikron Consultant
    Lecture Fees:
    FBhealth, Omikron,

Richard Dodel

  • Consulting Fees:
    Abbvie (2016), Contingo Consulting (2014), DZNE (2015-2017), Lilly (2009-2017), Novartis (2015), Octapharma (2016), Group H (2014), Piramal (2014), Axon Neuroscience (2016-2018)
    Lecture Fees:
    Abbvie (2014), Novartis (2016), Pfizer (2017), Thieme Verlag (2014, 2015), Med Update (2014, 2015), Studienstiftung des deutschen Volkes (2014-2017)
    Patents/Royalties
    6 patents
    Grants
    • Agency: 
      Baxter
      Dates: 
      2012-2016
    • Agency: 
      Deutsche Parkinson Vereinigung
      Dates: 
      (2008-2016),
    • Agency: 
      Faber Stiftung
      Dates: 
      2016
    • Agency: 
      Hector Stiftung
      Dates: 
      2010-2014
    • Agency: 
      Internationale Parkinson Fonds
      Dates: 
      2013-2015
    • Agency: 
      Michael J Fox Foundation
      Dates: 
      2016-2017
    • Agency: 
      AOK Gesundheitskasse Hessen
      Dates: 
      2015-2016
    • Agency: 
      AOK Gesundheitskasse Sachsen und Thüringen
      Dates: 
      2015-2016

Michael Happich

  • Equity:
    I own stocks from Eli Lilly
    Sponsors:
    I am employee at Eli Lilly

Josep Maria Haro

  • Consulting Fees:
    I have received consulting fees from Lilly, Lundbeck and Otsuka
    Lecture Fees:
    I have received consulting fees from Lilly and Otsuka

Roy W. Jones

  • Consulting Fees:
    Advisory Boards for Eli Lilly, MSD, Novartis and Otsuka; Data Monitoring Committee member for studies sponsored by Lundbeck, Novartis/Banner/NIH and Roche.
    Lecture Fees:
    Lecture fees and/or chairing symposia for Eli Lilly and Biogen

Catherine Reed

  • Equity:
    minor shareholder Eli Lilly and Company
    Sponsors:
    part-time employee at Eli Lilly and Company

Bruno Vellas

  • Consulting Fees:
    Lily, Merck, Otsuka, Acadia, nestle
    Grants
    • Agency: 
      nestle, lily, pierre fabre, acadia, merck

Anders Wimo

  • Consulting Fees:
    Eli Lilly Biogen Axoivant Nutricia Lundbeck Novartis